A mixed adenoneuroendocrine carcinoma of the pancreas: a case report
Open Access
- 15 November 2016
- journal article
- case report
- Published by Springer Science and Business Media LLC in Surgical Case Reports
- Vol. 2 (1), 1-6
- https://doi.org/10.1186/s40792-016-0263-1
Abstract
A tumor consisting of an adenocarcinoma component and a neuroendocrine carcinoma component, with each component accounting for at least 30% of the tumor, is defined as a mixed adenoneuroendocrine carcinoma (MANEC). We report a case of MANEC of the pancreas. A 63-year-old man presented with hyperglycemia and was referred to our hospital for further examination. Abdominal contrast-enhanced computed tomography (CT) revealed a mass of 2 cm in size in the pancreas head with portal vein narrowing. Fluorin-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) CT revealed increased accumulation in the mass of the pancreas head. Endoscopic retrograde cholangiopancreatography (ERCP) showed severe narrowing of the main pancreatic duct. Cytological analysis by endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) suggested a neuroendocrine tumor. Under the diagnosis of neuroendocrine tumor, pancreaticoduodenectomy with portal vein resection and regional lymph node dissection was performed with curative intent. Histological examination revealed that the tumor consisted of two cell populations. One was well- to moderately differentiated tubular adenocarcinoma. This cell component accounted for 45% of the whole tumor. The second component was non-adenocarcinoma cells arranged in a nest, and the cells had round nuclei, abundant cytoplasm, and coarse chromatin. The Ki67 labeling index was 40%. Immunohistochemically, the adenocarcinoma cells were positive for CEA but negative for chromogranin A (CgA) and synaptophysin (Syn), while the non-adenocarcinoma cells were positive for the expression of CgA and Syn but negative for CEA. Based on the findings, a diagnosis of MANEC of the pancreas was made. Postoperatively, lymph node metastasis and peritoneal dissemination developed rapidly and he died the 6 months after the operation. Due to the small number of reported cases of MANEC of the pancreas, its clinical behavior remains unclear and a standardized management protocol has not been established. Further investigation of more cases of this rare entity is necessary.Keywords
This publication has 19 references indexed in Scilit:
- Mixed Adenoneuroendocrine Carcinoma of Cecum: A Rare EntityJournal of Clinical Imaging Science, 2013
- EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysisGastrointestinal Endoscopy, 2012
- Mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: A possible stem cell tumor?Pathology International, 2011
- Mixed Exocrine and Endocrine Carcinoma in the Stomach: A Case ReportJournal of Gastric Cancer, 2011
- Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and PancreasJapanese Journal of Clinical Oncology, 2010
- Solitary concomitant endocrine tumor and ductal adenocarcinoma of pancreasWorld Journal of Gastroenterology, 2010
- Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)Japanese Journal of Clinical Oncology, 2008
- Intraductal growth of a nonfunctioning endocrine tumor of the pancreasThe Esophagus, 2004
- Mixed ductal-pancreatic polypeptide-cell carcinoma of the pancreasHistopathology, 2002
- Cancer of the Exocrine Pancreas: The Pathologic AspectsCA: A Cancer Journal for Clinicians, 1985